Determinants of discontinuation of ropinirole or pramipexole treatment in patients with Parkinson's disease: a retrospective study.
- Conditions
- 10028037Parkinson's disease
- Registration Number
- NL-OMON31064
- Lead Sponsor
- Medisch Spectrum Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
Outpatients with Parkinson's disease, who gave informed consent to obtain their drug history, and who had at least one prescription ropinirole and/or pramipexole, and who give informed consent for this study.
Exclusion Criteria
No exclusion criteria will be applied.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The endpoint of our retrospective cohort is the combined discontinuation of<br /><br>ropinirole or pramipexole treatment. The main study parameter is a Dopamine<br /><br>receptor (DR)D3 polymorphism.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Other study parameters such as gender, age at the index date, daily levodopa<br /><br>dosage, the average dose of dopamine agonist, concomitant use of<br /><br>antiparkinsonian drugs, antidepressants or antipsychotics, duration of PD and a<br /><br>Chronic Disease Score. Also one other polymorphism of DRD3, and polymorphisms<br /><br>of DRD2 and DRD4.</p><br>